For healthcare professionals only

Letters Screening and treatment for hepatitis C

Reducing the price of new hepatitis C drugs in the Tuscany region of Italy

BMJ 2015; 350 doi: (Published 24 June 2015) Cite this as: BMJ 2015;350:h3363
  1. Maurizia R Brunetto, director, hepatology unit1,
  2. Andrea De Luca, director, infectious diseases unit2,
  3. Andrea Messori, head, health technology assessment unit of ESTAR3,
  4. Anna Linda Zignego, director, centre for systemic manifestations of hepatitis viruses4
  1. 1Hepatology Unit, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy
  2. 2Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese and Department of Biotechnology, University of Siena, Siena, Italy
  3. 3Health Technology Assessment (HTA) Unit, Regional Health Service, ESTAR-Tuscany Region, Florence, Italy
  4. 4Department of Internal Medicine, Centre for Systemic Manifestations of Hepatitis Viruses, University of Florence, Largo Brambilla 3, Florence, Italy
  1. md3439{at}

In most European countries, regulatory agencies are engaged in approving reimbursement schemes for the new interferon-free direct antiviral agents (DAAs) for hepatitis C.1 2 The degree of reimbursement differs across countries and sometimes between regions of the same country.

Owing to budget constraints, most national approvals for reimbursement have been restricted to patients with more severe disease, according to ethical and clinical considerations.2 3 4 5

In May 2015, the Tuscany region of Italy proposed a regional tendering …

View Full Text

Log in

Log in through your institution


* For online subscription